| Maria D Mallory, MD | |
|
1200 6th Ave N, Saint Cloud, MN 56303-2735 | |
| (320) 252-5131 | |
| (320) 240-2118 |
| Full Name | Maria D Mallory |
|---|---|
| Gender | Female |
| Speciality | General Surgery |
| Experience | 24 Years |
| Location | 1200 6th Ave N, Saint Cloud, Minnesota |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689664344 | NPI | - | NPPES |
| 1043623 | Other | PREFERRED ONE | |
| HP52031 | Other | HEALTH PARTNERS | |
| 1701414 | Other | MEDICA HEALTH PLANS | |
| 346G4MA | Other | BLUE CROSS BLUE SHIELD | |
| 132828 | Other | U CARE | |
| 2357287 | Other | ARAZ GROUP AMERICAS PPO | |
| 6D053CE | Other | BLUE CROSS BLUE SHIELD | |
| 754479100 | Other | MEDICAL ASSISTANCE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 47718 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Cloud Hospital | Saint cloud, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Centracare Clinic | 2466363395 | 632 |
| St Cloud Hospital | 4880594779 | 188 |
News Archive
For the first time, researchers are using proteomics to examine proteins and peptides in saliva in order to accurately detect exposure to Zika virus.
New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.
Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.
An international team of researchers has identified a key protein involved in the immune system's response to malaria, tuberculosis (TB) and a number of other infectious diseases. The insights suggest possible new therapies to tackle these major global diseases.
› Verified 2 days ago
| Entity Name | Centracare Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043212665 PECOS PAC ID: 2466363395 Enrollment ID: O20031105000293 |
News Archive
For the first time, researchers are using proteomics to examine proteins and peptides in saliva in order to accurately detect exposure to Zika virus.
New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.
Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.
An international team of researchers has identified a key protein involved in the immune system's response to malaria, tuberculosis (TB) and a number of other infectious diseases. The insights suggest possible new therapies to tackle these major global diseases.
› Verified 2 days ago
| Entity Name | Centracare Health System - Melrose |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720045073 PECOS PAC ID: 1658270368 Enrollment ID: O20031231000690 |
News Archive
For the first time, researchers are using proteomics to examine proteins and peptides in saliva in order to accurately detect exposure to Zika virus.
New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.
Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.
An international team of researchers has identified a key protein involved in the immune system's response to malaria, tuberculosis (TB) and a number of other infectious diseases. The insights suggest possible new therapies to tackle these major global diseases.
› Verified 2 days ago
| Entity Name | Centracare Health System - Long Prairie |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164471678 PECOS PAC ID: 3870524598 Enrollment ID: O20050823000460 |
News Archive
For the first time, researchers are using proteomics to examine proteins and peptides in saliva in order to accurately detect exposure to Zika virus.
New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.
Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.
An international team of researchers has identified a key protein involved in the immune system's response to malaria, tuberculosis (TB) and a number of other infectious diseases. The insights suggest possible new therapies to tackle these major global diseases.
› Verified 2 days ago
| Entity Name | Centracare Health System - Melrose |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1720045073 PECOS PAC ID: 1658270368 Enrollment ID: O20060504000839 |
News Archive
For the first time, researchers are using proteomics to examine proteins and peptides in saliva in order to accurately detect exposure to Zika virus.
New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.
Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.
An international team of researchers has identified a key protein involved in the immune system's response to malaria, tuberculosis (TB) and a number of other infectious diseases. The insights suggest possible new therapies to tackle these major global diseases.
› Verified 2 days ago
| Entity Name | Centracare Health System - Long Prairie |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1164471678 PECOS PAC ID: 3870524598 Enrollment ID: O20061104000579 |
News Archive
For the first time, researchers are using proteomics to examine proteins and peptides in saliva in order to accurately detect exposure to Zika virus.
New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.
Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.
An international team of researchers has identified a key protein involved in the immune system's response to malaria, tuberculosis (TB) and a number of other infectious diseases. The insights suggest possible new therapies to tackle these major global diseases.
› Verified 2 days ago
| Entity Name | St Cloud Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043269798 PECOS PAC ID: 4880594779 Enrollment ID: O20110221000134 |
News Archive
For the first time, researchers are using proteomics to examine proteins and peptides in saliva in order to accurately detect exposure to Zika virus.
New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.
Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.
An international team of researchers has identified a key protein involved in the immune system's response to malaria, tuberculosis (TB) and a number of other infectious diseases. The insights suggest possible new therapies to tackle these major global diseases.
› Verified 2 days ago
| Entity Name | Centracare Health System - Sauk Centre |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578813762 PECOS PAC ID: 4981857216 Enrollment ID: O20130116000380 |
News Archive
For the first time, researchers are using proteomics to examine proteins and peptides in saliva in order to accurately detect exposure to Zika virus.
New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.
Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.
An international team of researchers has identified a key protein involved in the immune system's response to malaria, tuberculosis (TB) and a number of other infectious diseases. The insights suggest possible new therapies to tackle these major global diseases.
› Verified 2 days ago
| Entity Name | Centracare Health System-nr Llc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1275872772 PECOS PAC ID: 3870739410 Enrollment ID: O20130426000215 |
News Archive
For the first time, researchers are using proteomics to examine proteins and peptides in saliva in order to accurately detect exposure to Zika virus.
New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.
Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.
An international team of researchers has identified a key protein involved in the immune system's response to malaria, tuberculosis (TB) and a number of other infectious diseases. The insights suggest possible new therapies to tackle these major global diseases.
› Verified 2 days ago
| Entity Name | Centracare Health System-nr Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558600874 PECOS PAC ID: 3870739410 Enrollment ID: O20130515000683 |
News Archive
For the first time, researchers are using proteomics to examine proteins and peptides in saliva in order to accurately detect exposure to Zika virus.
New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.
Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.
An international team of researchers has identified a key protein involved in the immune system's response to malaria, tuberculosis (TB) and a number of other infectious diseases. The insights suggest possible new therapies to tackle these major global diseases.
› Verified 2 days ago
| Entity Name | Centracare Health-paynesville Llc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1205269941 PECOS PAC ID: 1153555719 Enrollment ID: O20131108000012 |
News Archive
For the first time, researchers are using proteomics to examine proteins and peptides in saliva in order to accurately detect exposure to Zika virus.
New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.
Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.
An international team of researchers has identified a key protein involved in the immune system's response to malaria, tuberculosis (TB) and a number of other infectious diseases. The insights suggest possible new therapies to tackle these major global diseases.
› Verified 2 days ago
| Entity Name | Centracare Health System - Sauk Centre |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1740553932 PECOS PAC ID: 4981857216 Enrollment ID: O20140523001292 |
News Archive
For the first time, researchers are using proteomics to examine proteins and peptides in saliva in order to accurately detect exposure to Zika virus.
New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.
Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.
An international team of researchers has identified a key protein involved in the immune system's response to malaria, tuberculosis (TB) and a number of other infectious diseases. The insights suggest possible new therapies to tackle these major global diseases.
› Verified 2 days ago
| Entity Name | Centracare Health-paynesville Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629402516 PECOS PAC ID: 1153555719 Enrollment ID: O20140909002390 |
News Archive
For the first time, researchers are using proteomics to examine proteins and peptides in saliva in order to accurately detect exposure to Zika virus.
New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.
Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.
An international team of researchers has identified a key protein involved in the immune system's response to malaria, tuberculosis (TB) and a number of other infectious diseases. The insights suggest possible new therapies to tackle these major global diseases.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Maria D Mallory, MD 1200 6th Ave N, Saint Cloud, MN 56303-2735 Ph: (320) 252-5131 | Maria D Mallory, MD 1200 6th Ave N, Saint Cloud, MN 56303-2735 Ph: (320) 252-5131 |
News Archive
For the first time, researchers are using proteomics to examine proteins and peptides in saliva in order to accurately detect exposure to Zika virus.
New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.
Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.
An international team of researchers has identified a key protein involved in the immune system's response to malaria, tuberculosis (TB) and a number of other infectious diseases. The insights suggest possible new therapies to tackle these major global diseases.
› Verified 2 days ago
Mark Engelsgjerd, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 251 County Rd 120, Saint Cloud, MN 56303 Phone: 320-202-8949 Fax: 320-202-0756 | |
Dr. Elizabeth Ann Tacl, M.D. Surgery Medicare: May Accept Medicare Assignments Practice Location: 1200 6th Ave N, Saint Cloud, MN 56303 Phone: 320-252-5131 | |
Dr. Liana M. Lugo, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 3701 12th St N, Suite 100, Saint Cloud, MN 56303 Phone: 320-253-7257 | |
Arnes Huskic, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 4801 Veterans Dr, Saint Cloud, MN 56303 Phone: 320-252-1670 | |
James L Jost, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 1200 6th Ave N, Saint Cloud, MN 56303 Phone: 320-252-5131 Fax: 320-240-2118 | |
Robert Shapiro, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 251 County Rd 120, Saint Cloud, MN 56303 Phone: 320-202-8949 Fax: 320-202-0756 | |
Stephen J Sahlstrom, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 1200 6th Ave N, Saint Cloud, MN 56303 Phone: 320-252-5131 Fax: 320-240-2118 |